glp 1/gip receptor agonist Dual GIP/GLP-1 agonists: New advances for treating type-2 diabetes Effects, working principles and target

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

It maintains saffrons native and complete composition (full spectrum), ensuring optimal synergy among its compounds for maximum efficacy

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

Lets start with the short summary (longer explanation below): SUPPORT GLP-1 PRODUCTION: In clinical studies Eriomins patented lemon bioflavonoid complex is shown to promote increased GLP-1 levels and support metabolic health.* GLP-1 Daily does not contain GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug